Table 1.
Participant characteristics by time of dropout
| Characteristics | Non-participantsa N = 951 |
Dropout T1 N = 856 |
Dropout T2 N = 219 |
Dropout T3/T4 N = 313 |
Full responders N = 1246 |
p value | |
|---|---|---|---|---|---|---|---|
| Sex | < 0.001 | ||||||
| Male | 458 (48%) | 432 (50%) | 119 (54%) | 177 (57%) | 723 (58%) | ||
| Female | 493 (52%) | 424 (50%) | 100 (46%) | 136 (43%) | 523 (42%) | ||
| Age (years), M (SD) | 70.9 (11.2) | 71.4 (9.3) | 70.5 (9.6) | 69.3 (9.8) | 67.9 (9.3) | < 0.001 | |
| Age (years) | < 0.001 | ||||||
| < 59 | 144 (15%) | 105 (12%) | 33 (15%) | 48 (15%) | 225 (18%) | ||
| 60–69 | 230 (24%) | 209 (24%) | 60 (27%) | 108 (35%) | 473 (38%) | ||
| 70–79 | 355 (37%) | 383 (45%) | 88 (40%) | 112 (36%) | 440 (35%) | ||
| 80< | 222 (23%) | 159 (19%) | 38 (17%) | 45 (14%) | 108 (9%) | ||
| Partner | < 0.001 | ||||||
| Yes | – | 600 (71%) | 166 (78%) | 239 (77%) | 979 (79%) | ||
| SES | < 0.001 | ||||||
| Low | 275 (29%) | 196 (23%) | 45 (21%) | 68 (22%) | 217 (17%) | ||
| Medium | 385 (40%) | 360 (42%) | 95 (43%) | 136 (44%) | 471 (38%) | ||
| High | 245 (26%) | 275 (32%) | 71 (32%) | 94 (30%) | 506 (41%) | ||
| Unknown/care institution | 46 (5%) | 25 (3%) | 8 (4%) | 15 (5%) | 52 (4%) | ||
| Education | < 0.001 | ||||||
| Low | – | 230 (27%) | 55 (25%) | 63 (20%) | 172 (14%) | ||
| Medium | – | 489 (57%) | 124 (57%) | 187 (60%) | 768 (62%) | ||
| High | – | 117 (14%) | 31 (14%) | 62 (20%) | 298 (24%) | ||
| Unknown | – | 20 (2%) | 9 (4%) | 1 (0%) | 8 (1%) | ||
| Clinical | Clinical | ||||||
| Years since diagnosis, M (SD) | 5.3 (2.9) | 5.3 (2.8) | 5.0 (2.8) | 5.1 (2.8) | 5.1 (2.8) | 0.52 | |
| Stage | 0.001 | ||||||
| I | 241 (25%) | 249 (29%) | 58 (26%) | 87 (28%) | 392 (31%) | ||
| II | 388 (41%) | 326 (38%) | 78 (36%) | 115 (37%) | 432 (35%) | ||
| III | 244 (26%) | 209 (24%) | 65 (30%) | 89 (28%) | 359 (29%) | ||
| IV | 50 (5%) | 56 (7%) | 14 (6%) | 12 (4%) | 31 (2%) | ||
| Unknown | 28 (3%) | 16 (2%) | 4 (2%) | 10 (3%) | 32 (3%) | ||
| Chemotherapy | 0.76 | ||||||
| Yes | 251 (26%) | 241 (28%) | 68 (31%) | 90 (29%) | 373 (30%) | ||
| Radiotherapy | 0.02 | ||||||
| Yes | 231 (24%) | 232 (27%) | 62 (28%) | 108 (35%) | 406 (33%) | ||
| Surgery | < 0.01 | ||||||
| Yes | 929 (98%) | 839 (98%) | 217 (99%) | 312 (100%) | 1240 (100%) | ||
| Comorbidities | < 0.01 | ||||||
| 0 | – | 183 (21%) | 45 (21%) | 83 (27%) | 303 (24%) | ||
| 1 | – | 201 (23%) | 52 (24%) | 71 (23%) | 385 (31%) | ||
| 2 | – | 170 (20%) | 48 (22%) | 71 (23%) | 266 (21%) | ||
| 3 or more | – | 202 (24%) | 60 (27%) | 71 (23%) | 241 (19%) | ||
| Unknown | – | 100 (12%) | 14 (6%) | 17 (5%) | 51 (4%) | ||
| Died before next invitation | 72 (28%) | 75 (13%) | 56 (31%) | 53 (20%) | – | < 0.001 | |
Note: p values report overall ANOVA for normally distributed continuous variables, chi-square tests for categorical variables, and Wilcoxon tests for non-normally distributed continuous variables. Means (M) with standard deviations (SD) were used to describe normally distributed continuous variables and frequencies with percentages were used to describe categorical variables
aInvited cancer survivors who declined to participate or had unverifiable addresses